Suppression of allergic encephalomyelitis in rats by means of antibrain serum.
Rats regularly develop evidence of allergic encephalomyelitis (AE) 2 to 3 weeks following sensitization to nervous tissue plus adjuvant. Independent of the severity of AE which occurs, gradual recovery is the rule and by the 6th to 9th week after sensitization rats appear clinically well and microscopic lesions of AE have virtually disappeared. Pooled serum collected from rats 3 or 6 weeks after sensitization contains complement-fixing (CF) antibrain antibodies. Such pooled serum exerts a striking suppressive influence on development of AE when passively administered to rats actively sensitized to nervous tissue. Serum pools which contain CF antibrain antibody suppress the disease. Serum pools lacking CF antibody do not suppress the disease. Serum containing CF antibrain antibody after treatment with 2-mercaptoethanol no longer fixes complement with brain antigen in vitro and no longer suppresses AE in vivo. The data suggest that transfer of protection against AE by passively administered antibrain rat serum is due to an antibrain antibody, possibly the CF antibodies. The meaning of these findings is discussed in terms of the role(s) of circulating antibrain antibody in the pathogenesis of AE.
D000818:Animals; D000906:Antibodies; D000937:Antigen-Antibody Reactions; D000941:Antigens; D001327:Autoimmune Diseases; D001921:Brain; D004679:Encephalomyelitis; D004681:Encephalomyelitis, Autoimmune, Experimental; D051381:Rats
D000906:Antibodies; D000941:Antigens
ANTIGEN-ANTIBODY REACTIONS; AUTOIMMUNE DISEASES; BRAIN; ENCEPHALOMYELITIS